With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott Park, Ill. (1888)
Health care equipment
Chairman/CEO Miles White (since 1999)
Return on Equity (average, past 3 years)
Cash / Debt
$8.5 billion / $7.1 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,617 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Undervalued stock as of right now. Biggest growth will come from emerging markets. Will need to deliver to those emerging markets if it will succeed -- which I think it can. A little worried about a major buyout of its major branches. ... Still a strong company with a good future.
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.
The article Why Abbott Labs Is Poised to Keep Poppin' originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.